Elisavet Serti Chrisos

Elisavet Serti Chrisos, MSc, Ph.D. is the Associate Director of Vaccines and Prevention at MHRP. Dr. Serti Chrisos has a strong background in clinical trials of vaccines and therapeutics of infectious and autoimmune diseases. She was previously a Project Leader for Vaccines and Infectious Diseases at the Emmes Corporation as well as the Associate Director of Biomarker Discovery and Research at the Immune Tolerance Network (Massachusetts General Hospital). She worked as Research Fellow and trained as a Post-Doctoral Fellow at the Immunology Section of the Liver Diseases branch of NIDDK/NIH for 6 years where she worked on clinical studies on hepatitis C infected patients with the goal of increasing treatment response of direct-acting antivirals.

Dr. Serti Chrisos received her bachelor’s degree in Biology from University of Patras in Greece (2004). She then attended University of Athens, Greece where she obtained her master’s in clinical Biochemistry and Molecular Diagnostics and her Ph.D. in Molecular Virology and Epidemiology (2011). Dr. Serti Chrisos is a member of the American Association of Virology (AAV), Federation of Clinical Immunology Societies (FOCIS), American Association for the Advancement of Science (AAAS), Society for Natural Immunity (SNI), American Association of Liver Disease (AASLD), American Association of Immunology (AAI) and a member and former President of Hellenic Bioscientific Association (HBA-USA). She is certified in Ethical and Regulatory Aspects of Clinical Research from the Maryland Nurses Association (2016) and in Technology Transfer and Patent Law from FAES NIH Graduate School (2021).

She has been recognized with several awards including the Norman P. Salzman Memorial Award in Virology for outstanding contribution in the field of Virology (2015), the NIH Director’s award for outstanding accomplishments as member of the NIH Ebola Patient Care Response Team (2015) and the Nancy Nossal Fellowship Award for Outstanding Grant Writing and Biomedical Research (2015).